Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Tabea Wilhelm

Treatment of Unresectable Stage IV Metastatic Melanoma With Aviscumine After Anti-Neoplastic Treatment Failure: A Phase II, Multi-Centre Study

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network

PLoS ONE
Multidisciplinary
2013English

Related publications

Paradigm Shift in the Treatment of Elderly Patients With Unresectable Stage IV Colorectal Cancer

Annals of Coloproctology
Gastroenterology
2014English

Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-Ii Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Targeting Epigenetics for Treatment of BRAF Mutated Metastatic Melanoma With Decitabine in Combination With Vemurafenib: A Phase Lb Study

Oncotarget
Oncology
2017English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Annals of Oncology
MedicineOncologyHematology
2017English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs
OncologyPharmacology
2011English

Front-Line Treatment With Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results From a Phase II Study

Urology
Urology
2016English

Evolving Treatment of Locoregional Metastatic Melanoma

English

A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy